Market Trends of France Neurology Devices Industry
This section covers the major market trends shaping the France Neurology Devices Market according to our research experts:
Neurosurgery Devices Expected to Witness Strong Growth
Neurosurgery devices are expected to witness significant growth in the coming years. This is majorly due to the increasing number of neurological disorders in France. For instance, according to the research study published in Frontiers Organization published in September 2022, the incidence of essential tremors was considerably high in France and reported a higher value of essential tremors among people aged 60 years and older.
Furthermore, PubMed data published in March 2022 stated that the rates of patients hospitalized for stroke increased among people aged under 65 years in France. Similarly, as per the report published by the Dijon Stroke Registry for France in March 2022, there will be an increase in the number of stroke cases in France by 2030 and 2050, associated with almost a doubling of healthcare costs related to stroke by then.
Additionally, another PubMed study published in January 2022 indicated that traumatic brain injury is a major public health concern in France, affecting mostly young patients, victims of road traffic accidents, elderly patients, and victims of falls. Intracranial pressure monitors are one of the key requirements for monitoring traumatic brain injuries. Thus, such a scenario is expected to increase the demand for the devices, thereby surging the market growth. Furthermore, the Alzheimer's Association stated that people with severe traumatic brain injury are at 4.5 times the risk of cognitive disorders such as dementia.
Interventional Neurology Devices Expected to Grow Significantly Over the Forecast Period
France's growing burden of neurological diseases is the leading factor responsible for segment growth. The French government is implementing various strategies to cope with this rising burden. For instance, in June 2021, the French Government published a Neurodegenerative Diseases Roadmap 2021-22, outlining steps that will be taken across different fields. Some of the key strategies of this roadmap include better access to research, the adaptation of hospital care (avoidance of inappropriate hospitalizations with upstream work and creation of resources for adapted hospital care), promoting French efforts in Europe, and exchanging best practices.
Some companies are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are collaborating with companies to introduce new products to retain their market share.
For instance, in June 2020, Denali Therapeutics and its development partner, Sanofi, announced that they may stop the development of the experimental drug, DNL747, used for the treatment of Alzheimer's, and may start research on a new drug candidate DNL788 for the same indications of Alzheimer's. Sanofi is responsible for developing DNL758 and is planning clinical trials in multiple indications based on successful Phase I data. Hence, with the above-mentioned factors, the segment is believed to witness strong growth in the coming years.
Additionally, the utilization of dementia policy is increasing in terms of awareness and monitoring purposes, fueling segment growth.
